



Pharmaceuticals in the Environment

European Union Strategic Approach

*DG ENV/C1
DG SANTE/B4*

One Health Aspect in Environmental Policies

“A Healthy Planet for Healthy People”

- Green Deal initiatives
 - Biodiversity Strategy
 - Farm to Fork Strategy
 - Chemicals Strategy
 - *Upcoming* Zero Pollution Action Plan
- But of course also already included before



Pharmaceuticals in the Environment

- European Union Strategic Approach to Pharmaceuticals in the Environment
 - Adopted March 2019
 - Whole lifecycle approach
 - From manufacturing through use to disposal
 - To be implemented in coordination between different actors




Strategic Approach to PiE

- 6 Areas of Action
 - Increase Awareness and Promote Prudent Use of Pharmaceuticals
 - Support Development of Pharmaceuticals Intrinsically Less Harmful for the Environment and Promote Greener Manufacturing
 - Improve Environmental Risk Assessment and Its Review
 - Reduce Wastage and Improve the Management of Waste
 - Expand Environmental Monitoring
 - Fill other Knowledge Gaps

Progress and Implementation

- Overall good progress
 - All actions at least started
 - Many well ongoing
 - Some already completed
- Current work streams DG ENV
 - Review of the Priority Substances List under the Water Framework Directive
 - Review of several Directives



EU Strategic approach

- Links also with the One Health Action Plan as regards the aspects related to the environment
- Implementation of certain actions on going via the Working Group focused on Pharmaceuticals in the environment under the pharmaceuticals Committee:
 - Prudent use of pharmaceuticals, including antibiotics to address pollution and AMR
 - Training of healthcare professionals
 - Improve Environmental risk assessment of human medicines
 - Reduce the waste, best practices for the safe disposal from pharmaceuticals: their pack sizes and the collection schemes of unused pharmaceuticals
 - Foster best practices on the environmental aspects via the advertisement

Pharmaceutical Strategy for Europe

- Links with the other EU Strategies: Green Deal and Industrial Strategy
- A holistic approach covering the full lifecycle of medicines
- Builds on the EU Strategic approach to PiE and the One Health Action Plan
- Sets flagship initiatives and actions :
- **High quality, safe and environmentally sustainable**
 - revise manufacturing and supply provisions in the legislation to **ensure environmental sustainability, quality and preparedness** (2022)
 - revise the legislation to strengthen **environmental risk assessment** requirements and conditions of use (2022)
- **Succeeding on the global level**
 - promote **regulatory convergence** to ensure access to safe, effective high-quality and affordable medicinal products globally (ongoing)

Collaboration in the implementation phase

This is a Pharmaceutical Strategy for Europe, therefore all actors at national and EU level need to coordinate on a common action plan which will span this Commission's mandate and beyond.

- Work together across disciplines and regulatory competences with a lifecycle-approach
- Active engagement with stakeholders and EU institutions
- Implementation plan developed in partnership with Member States
- Ensure continuity and close cooperation with Council Presidencies

Keep in touch



ec.europa.eu/



europa.eu/



[@EU_Commission](https://twitter.com/EU_Commission)



[@EuropeanCommission](https://www.facebook.com/EuropeanCommission)



[European Commission](https://www.linkedin.com/company/european-commission)



[europeancommission](https://www.instagram.com/europeancommission)



[@EuropeanCommission](https://medium.com/@EuropeanCommission)



[EUTube](https://www.youtube.com/EUTube)



[EU Spotify](https://open.spotify.com/EU_Spotify)



[@EU_Health](https://twitter.com/EU_Health) [#EUPharmaStrategy](https://twitter.com/EUPharmaStrategy)

Thank you



© European Union 2020

